Avadel Pharmaceuticals reported revenue targets for its narcolepsy treatment Lumryz that missed analyst estimates. The company said it expects net product revenue to be $240 million to $260 million in ...
Problem is, neither Rocket Lab, Planet Labs, nor AST are currently profitable, which makes them very hard to value -- because they literally have no P/E ratio to value them on. Faced with this ...